Arbutus Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Arbutus Biopharma wird ein Gewinn- und Umsatzwachstum von 11.7% bzw. 44.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 14.5% pro Jahr wachsen soll.

Wichtige Informationen

11.7%

Wachstumsrate der Gewinne

14.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	37.0%
Wachstumsrate der Einnahmen	44.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	20 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

LSE:0SGC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	8	-81	N/A	N/A	1
12/31/2025	5	-69	N/A	N/A	5
12/31/2024	6	-73	N/A	N/A	5
9/30/2024	7	-77	-72	-72	N/A
6/30/2024	10	-77	-73	-73	N/A
3/31/2024	13	-74	-79	-78	N/A
12/31/2023	18	-73	-87	-86	N/A
9/30/2023	22	-75	-87	-86	N/A
6/30/2023	24	-73	-84	-83	N/A
3/31/2023	33	-70	-84	-83	N/A
12/31/2022	39	-69	-36	-35	N/A
9/30/2022	36	-69	-38	-38	N/A
6/30/2022	33	-76	-36	-35	N/A
3/31/2022	21	-85	-30	-29	N/A
12/31/2021	11	-88	-68	-68	N/A
9/30/2021	10	-87	-64	-63	N/A
6/30/2021	8	-84	-60	-59	N/A
3/31/2021	8	-79	-54	-54	N/A
12/31/2020	7	-76	-52	-51	N/A
9/30/2020	6	-83	-50	-50	N/A
6/30/2020	8	-147	-61	-61	N/A
3/31/2020	7	-156	-70	-70	N/A
12/31/2019	6	-165	-72	-71	N/A
9/30/2019	6	-158	-75	-75	N/A
6/30/2019	5	-100	-65	-64	N/A
3/31/2019	5	-73	-65	-64	N/A
12/31/2018	6	-67	-69	-68	N/A
9/30/2018	7	-83	-62	-61	N/A
6/30/2018	12	-68	N/A	-64	N/A
3/31/2018	12	-86	N/A	-51	N/A
12/31/2017	11	-85	N/A	-49	N/A
9/30/2017	8	-267	N/A	-53	N/A
6/30/2017	2	-275	N/A	-52	N/A
3/31/2017	1	-387	N/A	-64	N/A
12/31/2016	1	-384	N/A	-58	N/A
9/30/2016	14	-171	N/A	-60	N/A
6/30/2016	18	-180	N/A	-47	N/A
3/31/2016	21	-65	N/A	-48	N/A
12/31/2015	23	-63	N/A	-56	N/A
9/30/2015	17	-62	N/A	-45	N/A
6/30/2015	17	-42	N/A	-49	N/A
3/31/2015	15	-33	N/A	-39	N/A
12/31/2014	15	-39	N/A	-12	N/A
9/30/2014	18	-35	N/A	-3	N/A
6/30/2014	17	-33	N/A	0	N/A
3/31/2014	18	-30	N/A	5	N/A
12/31/2013	15	-14	N/A	-7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 0SGC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 0SGC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 0SGC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 0SGCDie Einnahmen des Unternehmens (44.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.5% pro Jahr).

Hohe Wachstumseinnahmen: 0SGCDie Einnahmen des Unternehmens (44.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 0SGC in 3 Jahren voraussichtlich hoch sein wird

Arbutus Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Third quarter 2024 earnings released: US$0.10 loss per share (vs US$0.12 loss in 3Q 2023)

Arbutus Biopharma Corporation to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings released: US$0.10 loss per share (vs US$0.10 loss in 2Q 2023)

Arbutus Biopharma Corporation to Report Q2, 2024 Results on Aug 01, 2024

Arbutus Biopharma Corporation Announces New Preliminary End-Of- Treatment Data from the Phase 2A Clinical Trial

Arbutus Biopharma Corporation Announces New Data from its Phase 2a Clinical Trial IM-PROVE I (AB-729-201)

Whitefort Capital Management Sends an Open Letter to Shareholders of Arbutus Biopharma

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders

Whitefort Capital Management Engages with Arbutus Biopharma

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.10 loss per share (vs US$0.10 loss in 1Q 2023)

Arbutus Biopharma Corporation Announces Retirement of Chief Scientific Officer, Michael J. Sofia Effective December 31, 2024

Arbutus Biopharma Corporation to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Corporation, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: US$0.44 loss per share (vs US$0.46 loss in FY 2022)

Arbutus Biopharma Corporation to Report Q4, 2023 Results on Feb 29, 2024

Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline

Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD

Arbutus Biopharma Corporation Announces CEO Changes

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.12 loss in 3Q 2022)

Arbutus Biopharma Corporation to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Share price stability

Arbutus Biopharma Corporation Announces Pipeline Updates and Dosing of First Subject in Phase 1a/1b Clinical Trial with AB-101

Second quarter 2023 earnings released: US$0.10 loss per share (vs US$0.095 loss in 2Q 2022)

Arbutus Biopharma Corporation to Report Q2, 2023 Results on Aug 03, 2023

Arbutus Biopharma Corporation Announces the Appointment of Melissa V. Rewolinski to Its Board of Directors

Arbutus Biopharma Corporation Appoints Two New Executives

Arbutus Biopharma Corporation Appoints Two New Executives

Arbutus Doses First Patient in Additional Treatment Arm of Phase 2A Triple Combination Clinical Trial That Includes A Pd-1 Monoclonal Antibody

Arbutus Biopharma Corporation to Present AB-729 and AB-836 Data at EASL Congress 2023

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.11 loss in 1Q 2022)

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.83 loss in FY 2021)

Arbutus Biopharma Corporation Announces Resignation of Tram Tran from the Board of Directors, Effective on February 26, 2023

Arbutus Biopharma Corporation to Report Q4, 2022 Results on Mar 02, 2023

Arbutus Biopharma Corporation Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

Insufficient new directors

Arbutus Biopharma Corporation Appoints Mike Mcelhaugh as Chief Operating Officer, Effective as of November 1, 2022

Arbutus Biopharma Corporation Announces Resignation of Gaston Picchio as Chief Development Officer

Arbutus Biopharma Corporation to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: US$0.095 loss per share (vs US$0.23 loss in 2Q 2021)

Arbutus Biopharma Corporation to Report Q2, 2022 Results on Aug 04, 2022

Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with Ab-729 and Capsid Inhibitor

Arbutus Biopharma Corporation Presents New Data on AB-729, Ab-836 and AB-101 At the EASL International Liver Congress™ 2022 and Provides Ab-836 Clinical Update

Arbutus Biopharma Corporation and Vaccitech plc Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Insufficient new directors

First quarter 2022 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2021)

Arbutus Biopharma Corporation to Report Q1, 2022 Results on May 05, 2022

Arbutus Biopharma Corporation, Annual General Meeting, May 25, 2022

Arbutus Provides Pipeline Updates

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Arbutus Biopharma Corporation to Report Q4, 2021 Results on Mar 03, 2022

Antios Therapeutics and Arbutus Biopharma Announces First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection

Arbutus Biopharma Corporation announced that it expects to receive $14.999999 million in funding from Qilu Pharmaceutical Co., Ltd.

Arbutus Biopharma Corporation Announces Preliminary Data from its On-Going Phase 1A/1B Clinical Trial Demonstrating That its Next Generation Capsid Inhibitor, AB-836

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.27 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.23 loss per share (vs US$0.24 loss in 2Q 2020)

Arbutus Biopharma Corporation Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June

First quarter 2021 earnings released: US$0.21 loss per share (vs US$0.25 loss in 1Q 2020)

Arbutus Biopharma Corporation Receives Regulatory Approval to Initiate Phase 1a/1b Clinical Trial with AB-836, its Proprietary Oral Capsid Inhibitor for the Treatment of HBV Infection

Arbutus Biopharma Corporation, Annual General Meeting, May 26, 2021

Full year 2020 earnings released: US$1.00 loss per share (vs US$2.89 loss in FY 2019)

Revenue beats expectations

Assembly Biosciences, Inc. and Arbutus Biopharma Corporation Announce Initiation of Phase 2 Clinical Trial of Assembly Bio's Investigational Hepatitis B Virus Core Inhibitor Candidate

Arbutus Biopharma Corporation to Report Q4, 2020 Results on Mar 04, 2021

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken